Deutsche Bank’s Entrada Therapeutics TRDA Stock Holding History

Deutsche Bank’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$311K	Buy	24,679 +3,858	+19%	+$44.2K	﹤0.01%	2812
2025 Q4	$214K	Sell	20,821 -187	-0.9%	-$1.58K	﹤0.01%	2982
2025 Q3	$122K	Buy	21,008 +5,473	+35%	+$32K	﹤0.01%	3271
2025 Q2	$104K	Sell	15,535 -3,969	-20%	-$31.9K	﹤0.01%	3236
2025 Q1	$176K	Sell	19,504 -2,236	-10%	-$27.9K	﹤0.01%	3012
2024 Q4	$376K	Buy	21,740 +7,757	+55%	+$141K	﹤0.01%	2771
2024 Q3	$223K	Buy	13,983 +3,756	+37%	+$59.2K	﹤0.01%	2881
2024 Q2	$146K	Buy	10,227 +118	+1%	+$1.68K	﹤0.01%	2976
2024 Q1	$143K	Buy	10,109 +301	+3%	+$4.26K	﹤0.01%	3006
2023 Q4	$148K	Sell	9,808 -230	-2%	-$3.41K	﹤0.01%	3031
2023 Q3	$159K	Buy	10,038 +1,532	+18%	+$24.1K	﹤0.01%	2923
2023 Q2	$129K	Buy	+8,506	New	+$117K	﹤0.01%	3139
2022 Q2	–	Sell	-4,959	Closed	-$47K	–	4323
2022 Q1	$47K	Sell	4,959 -608	-11%	-$6.52K	﹤0.01%	3864
2021 Q4	$95K	Buy	+5,567	New	+$135K	﹤0.01%	3733

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank's TRDA Position: Q1 2026 in Review

Deutsche Bank increased its Entrada Therapeutics (TRDA) stake by 19% in Q1 2026, buying an estimated $44.2K and bringing the position to 24,679 shares worth $311K. The position accounts for ﹤0.01% of the portfolio, ranked #2812.

Deutsche Bank first reported a position in TRDA in Q4 2021 and has held it in 14 quarters since. The position peaked at $376K in Q4 2024. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

Deutsche Bank held 24,679 shares of Entrada Therapeutics worth $311K as of Q1 2026.
Deutsche Bank bought 3,858 Entrada Therapeutics shares in Q1 2026, an estimated $44.2K.
Entrada Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #2812 holding.
Deutsche Bank first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 14 quarters since.
Deutsche Bank's Entrada Therapeutics position peaked at $376K in Q4 2024.
120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.